Jade Biosciences financials
$14.18−1.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$58.9M | -$43.4M | -$27.4M | -$27.8M |
| Net income | -$46.2M | -$33.1M | -$19.1M | -$24.6M |
| Net margin | — | — | — | — |
| Diluted EPS | $-0.76 | $-0.57 | $-0.48 | $-0.86 |
| EBITDA | -$58.9M | -$43.4M | -$27.4M | -$27.8M |
| Operating cash flow | -$43.7M | -$24.1M | -$22.1M | -$20.2M |
| Free cash flow | -$43.7M | -$24.1M | -$22.2M | -$20.3M |
| Diluted shares | 61.1M | 57.8M | 39.6M | 28.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $107.3M | $55.1M | $88.4M | $50.1M | $220.9M |
| Short-term investments | $354.0M | $256.2M | $247.7M | $148.8M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $472.1M | $319.4M | $349.8M | $202.4M | $224.0M |
| Total liabilities | $32.2M | $23.0M | $17.3M | $23.1M | $22.4M |
| Shareholders' equity | $439.9M | $296.5M | $332.5M | $179.3M | $201.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology